The phase II RETAIN-2 trial tested a response‑adapted bladder preservation approach for selected patients with muscle‑invasive bladder cancer (MIBC). Patients received neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) combined with nivolumab, followed by management decisions based on clinical restaging. The report includes clinical outcomes from RETAIN-2 and a retrospective tumor‑informed analysis of longitudinal plasma ctDNA dynamics from RETAIN1 and RETAIN2.
RETAIN-2 prospectively evaluated neoadjuvant AMVAC plus nivolumab with response‑adapted management guided by clinical restaging. Seventy‑one evaluable patients were enrolled in RETAIN-2. Details of eligibility criteria, exact restaging methods, and restaging time points were not reported in the source summary.
The trial met its primary endpoint. After a median follow‑up of 34.7 months, the 2‑year metastasis‑free rate was 77.5% across the evaluable cohort. A sensitivity analysis using time to metastasis produced a Kaplan‑Meier estimated 2‑year metastasis‑free probability of 83.7% overall.
Twenty‑two patients entered an active surveillance pathway as part of the response‑adapted strategy. Of these, 15 (68.2%) remained metastasis free with an intact, non‑irradiated bladder, while 3 (13.6%) developed metastatic disease. In the sensitivity analysis using time to metastasis, the 2‑year metastasis‑free probability for the active surveillance subgroup was estimated at 85.5%.
A retrospective tumor‑informed plasma ctDNA analysis was performed on samples from 111 patients pooled from the RETAIN1 and RETAIN2 studies. The analysis evaluated longitudinal ctDNA dynamics and explored associations between baseline and post‑treatment ctDNA status and clinical outcomes. Specific laboratory methods, assay sensitivity, and timing of plasma draws were not detailed in the source abstract.
Baseline and post‑treatment ctDNA positivity were associated with higher risk of metastatic progression and inferior overall survival in the pooled retrospective cohort. Among the patients managed with active surveillance who were ctDNA‑negative after treatment, the 2‑year Kaplan‑Meier estimated metastasis‑free probability was 91% and overall survival was 97%.
Notably, plasma ctDNA predicted metastatic progression but did not predict intravesical recurrence. The authors interpret this pattern as consistent with ctDNA reflecting occult systemic disease rather than bladder‑confined recurrence.
The RETAIN-2 results suggest that a response‑adapted bladder preservation strategy after neoadjuvant AMVAC plus nivolumab can achieve encouraging longer‑term outcomes in a selected MIBC population. The retrospective ctDNA results indicate that plasma ctDNA dynamics may help identify patients with occult systemic disease who are at higher risk for metastasis and worse survival, and conversely identify ctDNA‑negative patients who had favorable 2‑year metastasis‑free and overall survival estimates when managed with active surveillance.
These findings support further prospective evaluation of ctDNA‑guided strategies to refine selection for bladder preservation. However, because ctDNA did not predict intravesical recurrence, the authors emphasize the ongoing need for bladder‑directed surveillance and complementary urinary biomarkers when bladder preservation is pursued.
The ctDNA analysis reported here was retrospective and pooled across RETAIN1 and RETAIN2; the source does not provide assay specifics or full methodological details in the abstract. Prospective trials are needed to validate ctDNA‑guided selection and to determine how best to integrate plasma ctDNA with clinical restaging, imaging, and urinary biomarkers. The source underscores the necessity of continued bladder surveillance in preserved bladders.
The clinical trial is registered as NCT04506554. The IRB of Fox Chase Cancer Center provided ethical approval for the work. The authors declared no competing interests in the source. De‑identified patient‑level clinical data will be available upon scientifically sound request for academic use, subject to institutional review and a data access agreement; requests should be directed to the corresponding author and will be reviewed by Fox Chase Cancer Center.